This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis...
ElevateBio is seeking out partnerships for its lead gene therapy after the const...
ElevateBio is seeking out partnerships for its lead gene therapy after the const...
The cryoablation devicemaker Adagio Medical has opted to pause the European laun...
Battles with regulators, legal wrangles and threats from generic makers add to t...
FRIDAY, Feb. 28, 2025 -- For patients with moderate-to-severe plaque psoriasis,...
FRIDAY, Feb. 28, 2025 -- Low-dose semaglutide seems to reduce craving and certa...
FRIDAY, Feb. 28, 2025 -- Many patients with advanced cancer receive potentially...
FRIDAY, Feb. 28, 2025 -- For young people with type 1 diabetes, hybrid closed-l...
FRIDAY, Feb. 28, 2025 -- A rapid nanosensor assay that measures serum protease ...
FRIDAY, Feb. 28, 2025 -- Higher fish consumption is associated with slower disa...
FRIDAY, Feb. 28, 2025 -- Nonmalignant gynecological diseases (NMGD) are associa...
FRIDAY, Feb. 28, 2025 -- Individuals previously hospitalized for COVID-19 have ...
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak ...
HHS Secretary Robert F. Kennedy Jr. moved to rescind the longtime practice of gi...
European regulators “reaffirmed” a positive view of Eisai and Biogen’s Alzheimer...
The brain drug developer is continuing a trial despite a recommendation it be st...
The molecular glue wave that first began years ago is still swelling, with Eli L...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of f...
HHS Secretary Robert F. Kennedy Jr. moved to rescind the longtime practice of gi...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
The once high-flying Ginkgo Bioworks is further scaling back its Boston real est...
European Shortages Monitoring Platform (ESMP) workshop on application programmin...
Certificates Processing System: Demo & Q&A session for Industry stakeholders (H+...